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Objective: To investigate the effect of Cannabis sativa resin and/or tramadol, two
commonly drugs of abuse on acetylcholinesterase and butyrylcholinesterase activities as a
possible cholinergic biomarkers of neurotoxicity induced by these agents.
Methods: Rats were treated with cannabis resin (5, 10 or 20 mg/kg) (equivalent to the
active constituent D9-tetrahydrocannabinol), tramadol (5, 10 and 20 mg/kg) or tramadol
(10 mg/kg) combined with cannabis resin (5, 10 and 20 mg/kg) subcutaneously daily for
6 weeks. Acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) activities were
measured in brain and serum. We also measured the activity of paraoxonase-1 (PON1) in
serum of rats treated with these agents.
Results: (i) AChE activity in brain increased after 10–20 mg/kg cannabis resin (by 16.3–
36.5%). AChE activity in brain did not change after treatment with 5–20 mg/kg tramadol.
The administration of both cannabis resin (5, 10 or 20 mg/kg) and tramadol (10 mg/kg)
resulted in decreased brain AChE activity by 14.1%, 12.9% and 13.6%, respectively; (ii)
BChE activity in serum was markedly and dose-dependently inhibited by cannabis resin
(by 60.9–76.9%). BChE activity also decreased by 17.6–36.5% by 10–20 mg/kg tramadol
and by 57.2–63.9% by the cannabis resin/tramadol combined treatment; (iii) Cannabis
resin at doses of 20 mg/kg increased serum PON1 activity by 25.7%. In contrast, tra-
madol given at 5, 10 and 20 mg/kg resulted in a dose-dependent decrease in serum PON1
activity by 19%, 36.7%, and 46.1%, respectively. Meanwhile, treatment with cannabis
resin plus tramadol resulted in 40.2%, 35.8%, 30.7% inhibition of PON1 activity
compared to the saline group.
Conclusions: These data suggest that cannabis resin exerts different effects on AChE
and BChE activities which could contribute to the memory problems and the decline in
cognitive function in chronic users.1. Introduction
Cannabis sativa L (family Cannabaceae) (C. sativa) has
remained the most widely used and abused drug worldwide [1].
The two most common cannabis preparations are marijuanawhich is the dried ﬂowing tops and leaves of the female plants
and hashish which is the compressed resin. Cannabis has long
been used through the history of mankind for its recreational
properties. Cannabis consumers often report the subjective
feeling of “being high”, euphoria, altered time perception and
increased sensual awareness. With long-term cannabis appears
to impair several cognitive functions [2,3]. There is impairment of
short-term and working memory that might persist for variable
time after abstinence fromcannabis [4,5]. There is also aggravation of
pre-existing psychosis or even a likeness of developing psychosis in
cannabis users [4]. Brain MRI scans indicate structural changes inunder the CC BY-NC-ND license (http://
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while animal models shows neuronal degeneration [7,8] despite
neuroprotection against excitotoxic brain injury (glutamate-
induced death) being reported [9].
Only recently and with the identiﬁcation of the cannabinoid
receptors and their endogenous ligands, the biological action of
cannabis beings to be delineated. The C21 terpenophenolic can-
nabinoids are the unique constituents of the C. sativa plant of
which the principal psychoactive ingredient is D9-tetrahydrocan-
nabinol (D9-THC). Other cannabinoids such as cannabinol, can-
nabidiol, cannabivarin, cannabichromene, and cannabigerol are
devoid of psychotropic action and might even antagonize some of
the pharmacological effects of D9-THC. This and other cannabi-
noids exist as their carboxylic acids and are converted (decar-
boxylated) into their corresponding phenols upon heating [10,11].
Cannabinoids or their endogenous ligands bind to cannabinoid
receptors CB1 and CB2 with the former being predominantly
expressed in the brain and spinal cord and thus mediates most of
the effects of cannabis on the central nervous system. On the
other hand, the CB2 receptor is mainly expressed on the surface
of the immune cells in the periphery [12].
Tramadol is a frequently prescribed centrally acting analgesic
with m-opioid receptor agonist properties. It also inhibits the re-
uptake of serotonin, and noradrenaline in the brain [13]. It is used to
treat acute pain and ofmoderate tomoderately severe chronic pain
resulting frommusculoskeletal disorders or that due to cancer [14].
The drug is becoming increasingly popular in several countries as
a drug of misuse [15–17]. Subjects taking 675 mg or more of
tramadol for 5 years or more exhibited an increase in comorbid
anxiety, depressive, and obsessive-compulsive symptoms [17].
There is also an evidence of memory impairing action for
tramadol [18]. Cannabis users are more likely to report use of
other illicit drugs [20] including tramadol [19].
In brain, central cholinergic neurotransmission is crucial for
cognitive functions including learning and memory formation
[21]. Inhibitors of brain acetylcholinesterase such as donepezil and
rivastigmine are the drugs being used to treat the cognitive
decline due to aging or Alzheimer's disease by increasing
extracellular acetylcholine, the signaling neurotransmitter of the
cholinergic system [22]. Changes in central cholinergic activity
thus will have an important impact on cognitive functions [21].
The aim of this study was therefore to investigate the effect of
cannabis and/or tramadol on the activities of brain
acetylcholinesterase and plasma butyrylcholinesterase, the
enzymes involved in the hydrolysis of the acetylcholine [23].
We in addition measured the activity of paraoxonase-1 (PON1)
in serum of rats treated with cannabis and/or tramadol. The PON1
enzyme is involved in the detoxiﬁcation of several organophos-
phorus compounds and many other xenobiotics and changes in its
activity have been associated with a number of neurologic dis-
orders [24,25].
2. Materials and methods
2.1. Animals
Male Sprague–Dawley rats, obtained from Animal House of
the National Research Centre, Cairo, weighing between 130 and
140 g were group-housed under temperature- and light-
controlled conditions with standard laboratory rodent chow
and water provided ad libitum. Animal procedures were per-
formed in accordance with the Ethics Committee of the NationalResearch Centre and followed the recommendations of the Na-
tional Institutes of Health Guide for Care and Use of Laboratory
Animals (Publication No. 85-23, revised 1985).2.2. Drugs and chemicals
C. sativa resin (Hashish) and tramadol were kindly provided
by the Laboratory of Forensic Sciences of Ministry of Justice
(Cairo, Egypt). Other chemicals and reagents were obtained
from Sigma Chemical Co. (St. Louis, MO, U.S.A).
2.3. Preparation of cannabis resin extract
Cannabis resin extract was prepared from the dried resin of
C. sativa. The extraction was performed using chloroform ac-
cording to the method of Turner and Mahlberg [26] with
modiﬁcation. In brief, 10 g of the resin was grounded in a
mortar, subjected to oven heat (100 C) for 1 h to decarboxylate
all its cannabinolic acids content. The resin was extracted in
chloroform overnight and ﬁltered. The ﬁltrate was evaporated
under a gentle stream of nitrogen and stored at 4 C and
protected from light in an aluminum-covered container. 1 g of
the residue (dry extract) was suspended in 2% ethanol-saline.
D9-tetrahydrocannabinol (D9-THC) content was quantiﬁed us-
ing gas chromatography–mass spectrometry (GC–MS). The resin
contained ~20% D9-THC and 3% cannabidiol.
2.4. Study design
Rats were treated withC. sativa resin extract at 5, 10 or 20 mg/
kg (expressed as D9-tetrahydrocannabinol), tramadol at 5, 10 or
20 mg/kg or tramadol (10 mg/kg) in combination with C. sativa
resin (5, 10 or 20 mg/kg) subcutaneously daily for 6 weeks. Rats
were randomly divided into ten groups, six rats each. Group 1
received the vehicle (0.2 mL saline) daily. Group 2, 3, 4 received
C. sativa resin at the doses of 5, 10 and 20 mg/kg, subcutaneously
daily.Groups 5, 6, 7 received tramadol at doses of 5, 10 and 20mg/
kg subcutaneously daily. Groups 8, 9, 10 received tramadol at
10 mg/kg in combination with C. sativa resin (5, 10 or 20 mg/kg,
subcutaneously daily). Rats were then euthanized by decapitation
under ether anesthesia for tissue collection. The brain of each rat
was rapidly dissected and snap-frozen in liquid nitrogen. Tissue
samples were stored at −80 C until further processing. Frozen
samples were thawed and homogenized in a glass tube with a
Teﬂon dounce pestle in ice-cold phosphate buffer solution
(50 mM Tris–HCl, pH 7.4) and sonicated. Homogenized samples
were then centrifuged at 9 000 g for 5min at 4 C. The supernatant
was stored at −80 C until further analysis.
2.5. Determination of acetylcholinesterase activity
The procedure used was a modiﬁcation of the method of
Ellman et al. [27] as described by Gorun et al. [28]. The principle
of the method is the measurement of the thiocholine produced as
acetylthiocholine is hydrolyzed. The color was read immediately
at 412 nm.
2.6. Determination of butyrylcholinesterase activity
Butyrylcholinesterase activity was measured spectrophoto-
metrically using commercially available kit (Ben Biochemical
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the hydrolysis of butyrylthiocholine, forming butyrate and thi-
ocholine. The thiocholine reacts with dithiobis-nitrobenzoic acid
(DTNB) forming a colored compound. The increase in absor-
bance in the unit time at 405 nm is proportional at the activity of
the cholinesterase in the sample.Sa
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Figure 1. Brain acetylcholinesterase (AChE) activity in rats treated with
cannabis resin, tramadol or both.
*P < 0.05 vs. saline group and between different groups as indicated in the
ﬁgure. +P < 0.05 vs. only cannabis resin at 10 or 20 mg/kg.
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Figure 2. Serum butyrylcholinesterase (BChE) activity in rats treated with
cannabis resin, tramadol or both.
*P < 0.05 vs. saline group and between different groups as indicated in the
ﬁgure. +P < 0.05 vs. only cannabis resin. #P < 0.05 vs. only tramadol.2.7. Determination of paraoxonase activity
Arylesterase activity of paraoxonase was measured spectro-
photometrically using phenylacetate as a substrate [29,30]. In this
assay, arylesterase/paraoxonase catalyzes the cleavage of phenyl
acetate resulting in phenol formation. The rate of formation of
phenol is measured by monitoring the increase in absorbance at
270 nm at 25 C. The working reagent consisted of 20 mM Tris/
HCl buffer, pH 8.0, containing 1 mM CaCl2 and 4 mM phenyl
acetate as the substrate. Samples diluted 1:3 in buffer are added
and the change in absorbance is recorded following a 20 s lag
time. Absorbance at 270 nm was taken every 15 s for 120 s.
One unit of arylesterase activity is equal to 1 mM of phenol
formed per minute. The activity is expressed in kU/L, based on
the extinction coefﬁcient of phenol of 1 310 m/cm at 270 nm,
pH 8.0 and 25 C. Blank samples containing water are used to
correct for the spontaneous hydrolysis of phenylacetate.
2.8. Statistical analysis
Data are expressed as mean ± SE. Data were analyzed by
one-way analysis of variance, followed by Duncan's multiple
range test for post hoc comparison of group means. Effects with
a probability of P < 0.05 were considered to be signiﬁcant.
3. Results
3.1. Acetylcholinesterase activity
Signiﬁcant increase in brain AChE activity by 16.3% and
36.5% was observed in rats treated with 10–20 mg/kg cannabis
resin alone compared to the saline control group
[(9.84 ± 0.31) mmol SH/g/min, (11.55 ± 0.45) mmol SH/g/min
vs. (8.46 ± 0.22) mmol SH/g/min]. No signiﬁcant change in
AChE activity was found after tramadol. The combined
administration of cannabis resin/tramadol was, however, asso-
ciated with signiﬁcant decrease in brain AChE activity by
14.1%, 12.9%, and 13.5%, respectively [(7.27 ± 0.22) mmol SH/
g/min, (7.37 ± 0.26) mmol SH/g/min, (7.32 ± 0.300 mmol SH/g/
min vs. (8.46 ± 0.22) mmol SH/g/min)] (Figure 1).
3.2. Butyrylcholinesterase activity
Cannabis resin alone at a dose of 5, 10 and 20 mg/kg caused
signiﬁcant inhibition in serum BChE activity by 60.9%, 67.0%
and 76.9% compared to the saline control group
[(90.91 ± 2.80) U/L, (76.73 ± 4.20) U/L, (53.76 ± 3.10) U/L vs.
(232.72 ± 5.90) U/L] (Figure 2). Serum BChE activity was also
signiﬁcantly decreased by 10–20 mg/kg tramadol (17.2% and
36.5% decrease: [(192.71 ± 4.90) U/L, (147.74 ± 2.60) U/L vs.
(232.72 ± 5.90) U/L]) and following treatment with both
cannabis resin and tramadol (57.2%, 62.6%, and 63.9%
decrease: [(99.70 ± 6.00) U/L, (87.00 ± 4.10) U/L,
(84.10 ± 3.30) U/L vs. (232.72 ± 5.90) U/L]).3.3. Paraoxonase 1 activity
In serum, a signiﬁcant and marked increase in PON1 activity
was observed after treatment with 20 mg/kg of cannabis resin
compared to the saline group by 25.7%, [(76.1 ± 21.2) vs.
(299.2 ± 13.0) kU/L] (Figure 3). A signiﬁcant decrease in serum
PON1 activity by 19.0%, 36.7%, and 46.1% was observed after
the administration of 5, 10 and 20 mg/kg of tramadol, respec-
tively [(242.4 ± 19.1) kU/L, (189.3 ± 11.9) kU/L,
(161.1 ± 12.7) kU/L vs. (299.2 ± 13.0) kU/L]. Meanwhile,
treatment with cannabis resin plus tramadol resulted in
decreased PON1 activity by 40.2%, 35.8%, 30.7% compared to
the saline group [(179.0 ± 15.4) kU/L, (182.2 ± 8.8) kU/L,
(207.4 ± 16.9) kU/L vs. (299.2 ± 13.0) kU/L].
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Figure 3. Serum paraoxonase-1 (PON1) activity in rats treated with
cannabis resin, tramadol or both.
*P < 0.05 vs. saline group and between different groups as indicated in the
ﬁgure. +P < 0.05 vs. only cannabis resin at 10 or 20 mg/kg.
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In the current study, we show that treating rats with a
cannabis resin extract rich in delta 9-THC resulted in an increase
in brain acetylcholinesterase (AChE) activity and at the same
time caused marked inhibition of serum butyrylcholinesterase
(BChE) activity. The serine esterases AChE (EC 3.1.1.7.) and
BChE (EC 3.1.1.8.) can catalyze the hydrolysis of the neuro-
transmitter acetylcholine into choline and acetic acid. The
enzyme AChE is present in brain, autonomic ganglia, skeletal
muscle end-plate and in erythrocyte membrane. AChE hydro-
lyzes acetylcholine faster than the other choline esters. It is the
key enzyme which terminates the action of ACh at cholinergic
synapses and is highly efﬁcient in modulating the levels of
extracellular acetylcholine and in regulating cholinergic neuro-
transmission [31,32]. It is not surprising therefore that inhibitors
of AChE e.g., donepezil are used for boosting residual
cholinergic activity in Alzheimer's disease [33]. In this
neurodegenerative disorder, loss of cholinergic innervations
and deﬁcits in cholinergic neurotransmission underlie the
cognitive deterioration involving memory, language and higher
executive functioning [21].
It follows that the increase in brain AChE activity by the
cannabis resin observed in this study would result in decreased
brain levels of ACh, which could explain at least in part, the
cognitive and memory deﬁcits in heavy users of cannabis. In this
context, several studies have shown inhibition in extracellular
acetylcholine concentration in several brain areas following i.p.
injection of THC (3–6 mg/kg), the main active ingredient in
cannabis [34–36]. In cortical, hypothalamic and striatal rat brain
slices, both D8-THC and D9-THC were found to inhibit the
synthesis of 3H-ACh with D8-THC being twice as effective as
D9-THC. Meanwhile, the non-psychotropic cannabidiol did not
alter ACh synthesis [37]. In rat hippocampus, inhibition of ACh
release also followed i.p. injection of synthetic cannabinoids,
WIN 55,212-2 (5.0 and 10 mg/kg i.p.) and CP 55,94 (0.5 and
1.0 mg/kg i.p.) with the effect being blocked by the CB1antagonist SR 141716A [38]. On the other hand, very low
doses of D9-THC (10–150 mg/kg) or the cannabinoid CB1
receptor agonists WIN 55,212-2 (10–150 mg/kg) and HU 210
(1 and 4 mg/kg) given intravenously to freely moving rats
increased cortical and hippocampal acetylcholine release [39,40].
The chemistry of herbal cannabis, however, is complex, as
there are over 70 different cannabinoids identiﬁed so far [10].
Some cannabinoids potentiate whilst others e.g., cannabidiol
antagonize some of the pharmacological actions of the
principal and psychotropic one i.e., D9-THC [41]. Cannabis is
not merely cannabinoids and contains several terpenoids and
among these a-Pinene, a bicyclic monoterpene is an AChE
inhibitor [42]. Clearly, the net effect will therefore depends on
the relative contribution of different cannabis components and
it is possible that in high potency cannabis with high content
of D9-THC, the action of the latter will prevail/predominate.
Butyrylcholinesterase (EC 3.1.1.8; BChE) also known as
pseudocholinesterase or plasma cholinesterase is expressed in
many tissues but is found primarily in the liver and plasma. The
enzyme differs from AChE in substrate speciﬁcity. BChE,
preferentially hydrolyzes butyrylcholine and also acetylcholine
[23,43]. The exact physiological function of BChE is not
understood. It can hydrolyze heroin and might function as a
detoxifying enzyme for natural compounds. The genetic
deﬁciency of this enzyme in humans results in no apparent
physiological consequences [23]. The role of BChE in
cholinergic neurotransmission is also much less clear
compared with that of AChE. Recent evidence from rodent
experiments, however, suggests that, brain-targeted BChE in-
hibitors elevates extracellular ACh levels and improve the
cognitive performance of aged rats [44]. The ﬁndings in the
present study indicates that the cannabis resin extract exerted
marked inhibitory effect on serum BChE activity. It is not
clear whether the potent inhibition of BChE activity by the
cannabis resin will be reﬂected in decreased degradation of
brain ACh. This is because the hydrolysis of ACh is carried
out mainly by AChE, with a minor role for BChE if any
[23,43]. Moreover and as shown in this study, brain AChE
activity increased by the cannabis resin which will lead to
decreased brain ACh availability.
In the present study, we also demonstrated that the repeated
administration of cannabis resin extract increased paraoxonase-1
(PON1) activity in serum. This enzyme belongs to the para-
oxonase family which also comprises PON2 and PON3 iso-
forms. Paraoxonase 1 is a calcium-dependent esterase that
hydrolyzes the active metabolites (oxons) of several organo-
phosphorus insecticides including parathion, chlorpyrifos and
diazinon and an individual's PON1 status determines the sensi-
tivity to these chemicals. Paraoxonase 1 also hydrolyzes aro-
matic esters such as phenyl acetate (arylesterase activity) and a
variety of aromatic and aliphatic lactones (lactonase activity). It
is synthesized in the liver and released into blood where it binds
to high density lipoproteins and prevents their oxidation [24,30].
The activity of PON1 decreases in patients with Alzheimer's
disease and other dementias [45], and autism [46]. PON1
possesses an antioxidant role [24,30] and is inactivated by
increased oxidative stress [47,48] which might explain the
decrease in enzyme activity in patients suffering from these
neurologic disorders.
The present study also investigated the ability of tramadol, an
opiate like analgesic with abuse liability and addictive properties
[16,19,49] on the activity of AChE, BChE and PON1. In contrast
Omar M.E. Abdel-Salam et al./Asian Paciﬁc Journal of Tropical Medicine 2016; 9(11): 1089–1094 1093to the effect of the cannabis resin extract, we found that tramadol
did not alter AChE activity in the rat brain. When combined with
tramadol, cannabis, however, did not increase brain AChE
activity, thereby, suggesting a modulatory action for tramadol
on the cannabis-induced increase in AChE activity. In contrast,
BChE activity was inhibited by tramadol doses of 10 and 20 mg/
kg although to much less extent compared with the cannabis
resin. Serum BChE activity might thus serve as a marker in those
who abuse tramadol. Meanwhile, there was no additive effect for
the combination of cannabis-tramadol in inhibiting BChE activ-
ity. PON1 activity, however, was markedly inhibited by tramadol
and also by cannabis-tramadol. This ﬁnding is important in view
of the evidence that the catalytic efﬁciency of PON1 determines
the severity of toxicity following exposure to some of the
organophosphorus compounds [50,51]. Thus patients on tramadol
might be susceptible to some of the consequences of pesticide
exposure and among these lies the risk for developing
neurodegenerative disorders like Parkinson's disease or
Alzheimer's disease [25].
In summary, the ﬁndings of the present study suggest a
modulatory effect for cannabis resin extract on the activities of
AChE and BChE. This action of cannabis is likely to contribute
to the memory deﬁcits and the decline in cognitive function
observed in chronic users. The study also demonstrates an
inhibitory effect for tramadol on BChE and PON1 activities. It is
suggested that the changes in the activities of both enzymes
could be a marker for the drug-induced neurotoxicity.
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